After the Senate passed a major drug pricing reform Sunday, pharma companies are likely readying their legal slings and arrows. Meanwhile, industry watchers remain divided on the bill’s pros and cons.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,